X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1598) 1598
treatment-naive (1044) 1044
treatment-naive patients (1034) 1034
male (703) 703
female (690) 690
infectious diseases (639) 639
hepatitis c (595) 595
antiviral agents - therapeutic use (581) 581
hepatitis c virus (579) 579
middle aged (556) 556
adult (550) 550
pharmacology & pharmacy (548) 548
hepatitis c, chronic - drug therapy (532) 532
gastroenterology & hepatology (516) 516
ribavirin (516) 516
virology (474) 474
genotype (468) 468
hiv infections - drug therapy (458) 458
treatment outcome (449) 449
hepacivirus - genetics (422) 422
drug therapy, combination (420) 420
antiviral agents (415) 415
hiv (383) 383
hepatitis (332) 332
interferon (330) 330
immunology (322) 322
sofosbuvir (319) 319
hepacivirus - drug effects (313) 313
health aspects (312) 312
sustained virological response (309) 309
protease inhibitors (302) 302
drug therapy (295) 295
treatment-experienced patients (293) 293
genotype 1 infection (285) 285
hiv infections - virology (284) 284
therapy (283) 283
double-blind (278) 278
infection (278) 278
microbiology (278) 278
aged (275) 275
antiretroviral therapy (272) 272
drug resistance (260) 260
drug resistance, viral (254) 254
care and treatment (251) 251
pegylated interferon (251) 251
analysis (249) 249
mutation (237) 237
virus diseases (230) 230
efficacy (226) 226
hepatitis c - drug therapy (222) 222
hcv (221) 221
human immunodeficiency virus--hiv (221) 221
ribavirin - therapeutic use (221) 221
combination therapy (219) 219
hiv-1 - drug effects (218) 218
virus-infection (217) 217
viral load (215) 215
hepatitis c, chronic - virology (214) 214
patients (213) 213
plus ribavirin (213) 213
safety (207) 207
open-label (202) 202
antiviral agents - adverse effects (199) 199
hiv-1 - genetics (197) 197
genetic aspects (196) 196
antiviral agents - administration & dosage (194) 194
infections (194) 194
viruses (187) 187
anti-hiv agents - therapeutic use (181) 181
research (178) 178
young adult (176) 176
antiviral agents - pharmacology (169) 169
clinical trials (169) 169
simeprevir (167) 167
biological response modifiers (166) 166
genotype 1 (164) 164
prevalence (164) 164
cirrhosis (159) 159
medicine, general & internal (155) 155
peginterferon alpha-2a (154) 154
antiretroviral drugs (153) 153
genotype & phenotype (152) 152
genotypes (149) 149
interferon-alpha - therapeutic use (149) 149
drug resistance, viral - genetics (147) 147
proteases (147) 147
telaprevir (146) 146
hiv infection (145) 145
resistance (145) 145
hiv-1 (141) 141
combination (135) 135
direct-acting antivirals (135) 135
pharmacokinetics (132) 132
aids/hiv (131) 131
liver cirrhosis (129) 129
efavirenz (128) 128
protease inhibitor (126) 126
liver (125) 125
ledipasvir (124) 124
dosage and administration (123) 123
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2285) 2285
German (15) 15
Spanish (12) 12
French (10) 10
Japanese (6) 6
Portuguese (6) 6
Russian (4) 4
Hungarian (3) 3
Polish (2) 2
Norwegian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Expert Opinion on Investigational Drugs, ISSN 1744-7658, 2013, Volume 22, Issue 9, pp. 1107 - 1121
Introduction: Rapid breakthroughs in the treatment of hepatitis C virus (HCV) infection have dramatically altered the treatment landscape for this chronic... 
partial responders | boceprevir | NS5A inhibitors | null responders | pegylated interferon | relapsers | SVR | ABT-333 | danoprevir | simeprevir | telaprevir | hepatitis C virus | protease inhibitors | ABT-450 | cirrhosis | ribavirin | NS5B polymerase inhibitors | treatment naïve | asunaprevir | resistance | daclatasvir | ABT-267 | directly acting antiviral agents | ledipasvir | sofosbuvir | faldaprevir | cyclophilin inhibitors | mericitabine | Cyclophilin inhibitors | Simeprevir | Ledipasvir | Faldaprevir | Null responders | Telaprevir | Ribavirin | Daclatasvir | Treatment naïve | Directly acting antiviral agents | Asunaprevir | Danoprevir | Pegylated interferon | Partial responders | Mericitabine | Resistance | Cirrhosis | Boceprevir | Relapsers | Protease inhibitors | Hepatitis C virus | Sofosbuvir | VIRUS | NS3 PROTEASE | SUSTAINED VIROLOGICAL RESPONSE | PEGINTERFERON ALPHA-2A | HCV-RNA | PHARMACOLOGY & PHARMACY | TREATMENT-NAIVE PATIENTS | treatment naive | PROTEASE INHIBITOR | ORAL COMBINATION THERAPY | VIRAL RESPONSE | RIBAVIRIN P/R | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | United States | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Clinical Trials as Topic | Drug Approval | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Drug Design
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 24, pp. 2394 - 2395
An open-label pilot trial involving 10 patients shows that hepatitis C virus genotype 1–infected kidneys transplanted into HCV-negative recipients, followed by... 
MEDICINE, GENERAL & INTERNAL | VIRUS GENOTYPE 1 | TREATMENT-NAIVE | ELBASVIR | Hepacivirus - isolation & purification | Pilot Projects | Humans | Middle Aged | Hepatitis C - virology | Hepacivirus - genetics | RNA, Viral - analysis | Adult | Kidney Transplantation | Kidney - virology | Viral Load
Journal Article
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2018, Volume 67, Issue 5, pp. 687 - 692
Abstract Background Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia,... 
ibrutinib | infection | invasive fungal infection | INFECTIOUS DISEASES | X-LINKED AGAMMAGLOBULINEMIA | MICROBIOLOGY | INVASIVE FUNGAL-INFECTIONS | IMMUNOLOGY | TARGETING BTK | SINGLE-AGENT IBRUTINIB | BRUTONS TYROSINE KINASE | TREATMENT-NAIVE | THERAPY | PNEUMOCYSTIS-JIROVECII PNEUMONIA | B-CELL MALIGNANCIES | CHRONIC LYMPHOCYTIC-LEUKEMIA | and Commentaries
Journal Article